SRR15069605
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.420
- PANCREAS_BETA_CELLS+0.400
- COMPLEMENT+0.290
- IL6_JAK_STAT3_SIGNALING+0.250
- COAGULATION+0.200
- KRAS_SIGNALING_UP+0.170
- INFLAMMATORY_RESPONSE+0.140
- SPERMATOGENESIS+0.140
- ADIPOGENESIS+0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.080
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.520
- NOTCH_SIGNALING-0.470
- MYC_TARGETS_V2-0.430
- ESTROGEN_RESPONSE_EARLY-0.410
- G2M_CHECKPOINT-0.410
- MITOTIC_SPINDLE-0.410
- ESTROGEN_RESPONSE_LATE-0.370
- P53_PATHWAY-0.370
- CHOLESTEROL_HOMEOSTASIS-0.360
- E2F_TARGETS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202468 | — | — | 0.790 |
| 2 | SRR1516066 | — | — | 0.774 |
| 3 | SRR1465337 | GTEX | — | 0.773 |
| 4 | SRR1320892 | GTEX | — | 0.766 |
| 5 | SRR25617834 | — | D | 0.756 |
| 6 | MNG445 | — | — | 0.747 |
| 7 | TCGA-86-8076-01A-31R-2241-07 | — | cohortA1 | 0.740 |
| 8 | SRR1336887 | GTEX | — | 0.734 |
| 9 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.733 |
| 10 | 14a20c28-47d6-4c2d-98cf-6bf8aa2c386f | — | — | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.040 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.040 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |